"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...
While we have made progress with FDA approval of two treatments that can slow cognitive decline in early-stage Alzheimer’s ...
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...
A potential new treatment for Alzheimer’s disease may come in the form of a nasal spray. Researchers in Italy have discovered ...
Alzheimer’s disease remains one of the most pressing challenges in modern medicine, ranking as a leading cause of death ...
Scientists have created a game-changing 'Alzheimer's in a dish' model that allows for faster and more accurate testing of ...
Visceral fat has been linked to early Alzheimer’s disease pathology, according to a study of midlife individuals. Researchers ...
New research has established a link between a specific type of body fat and brain proteins that are hallmarks of Alzheimer's ...